...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Confirmation of mendelian properties of heterodimeric fibrinogen molecules in a heterozygotic dysfibrinogenemia, 'fibrinogen Amarillo,' using gprphoresis to differentiate semifibrin molecules from fibrinogen and fibrin.
【24h】

Confirmation of mendelian properties of heterodimeric fibrinogen molecules in a heterozygotic dysfibrinogenemia, 'fibrinogen Amarillo,' using gprphoresis to differentiate semifibrin molecules from fibrinogen and fibrin.

机译:在杂合性血纤维蛋白原缺乏症(“ Abrillo纤维蛋白原”)中,采用gprphoresis技术将半纤维蛋白分子与纤维蛋白原和纤维蛋白区分开来,以确认孟德尔二聚体纤维蛋白原分子的孟德尔特性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The fibrinogen molecule consists of two sets of Aalpha, Bbeta, and gamma chains assembled into a bilateral disulfide linked (Aalpha, Bbeta, gamma)2 structure. Cleavage of the two A-fibrinopeptides (FPA, Aalpha1-16) from normal Aalpha chains with arginine at position 16 (RFPA) by thrombin or the venom enzyme atroxin transforms fibrinogen into self-aggregating fibrin monomers (alpha, Bbeta, gamma)(2). Mutant Aalpha16R-->H fibrinopeptide (HFPA) cannot be cleaved from fibrinogen by atroxin. Many studies on heterozygous dysfibrinogenemias with this mutation suggested that incorporation of the mutant chains into the molecules was ordered in a manner yielding only (1) homodimeric normal (RFPARFPA) atroxin-coagulable molecules and (2) homodimeric abnormal (H(FPA)HFPA) atroxin-incoagulable molecules in equal quantities. Although heterodimeric molecules (RFPAHFPA) could not be found in studies on the intact protein, Meh et al. demonstrated their existence by showing that CNBr digests of fibrinogens from atroxin-treated Aalpha16R-->H heterozygotic dysfibrinogenemias consistently yielded N-terminal fragments (NDSKs) with partially resolved electrophoretic bands predominantly in between the NDSKs of fibrinogen and alpha-fibrin. An opportunity to confirm and better quantify the heterodimers arose with the recent development of a method (GPRphoresis) for identifying molecules lacking only one FPA, which is applied here in study of a newly presenting case of an Aalpha16R-->H dysfibrinogenemia, "fibrinogen Amarillo." GPRphoresis uses electrophoretic shifts, staged with GPRP-NH(2) to separate the self-aggregating fibrin monomers lacking both FPAs from weakly aggregating "semifibrin" molecules lacking one FPA An antifibrin alpha17-23 antibody is used to measure and differentiate the semifibrin from fibrinogen with FPA fully intact. Applying GPRphoresis to atroxin digests of fibrinogen Amarillo clearly demonstrated RFPARFPA, RFPAHFPA, and HFPAHFPA molecules in nearly perfect Mendelian 1:2:1 proportions. In turn, the high levels of the semifibrin in the terminal atroxin digests provide genetic phenotypic evidence supporting fidelity of the GPRphoresis method.
机译:纤维蛋白原分子由组装成双边二硫键连接的(Aalpha,Bbeta,γ)2结构的两组Aalpha,Bbeta和γ链组成。凝血酶或毒酶atroxin从正常Aalpha链上的16位精氨酸(RFPA)切割掉正常Aalpha链上的两个A-纤维蛋白肽(FPA,Aalpha1-16)将纤维蛋白原转化为自聚集的纤维蛋白单体(α,Bbeta,γ)(2 )。突变的Aalpha16R-> H纤维蛋白肽(HFPA)不能被Atroxin从纤维蛋白原上切割下来。关于具有这种突变的杂合性纤维蛋白原血过多的许多研究表明,以仅产生(1)同型二聚体正常(RFPARFPA)融合蛋白凝集素的分子和(2)同型二聚体异常(H(FPA)HFPA)的方式将突变链掺入分子是有序的。等量的可融合抗氧剂的分子。尽管在完整蛋白的研究中未发现异二聚体分子(RFPAHFPA),通过显示来自Atroxin处理的Aalpha16R-> H杂合性dysfibr纤维蛋白原血症的纤维蛋白原的CNBr消化液持续产生N端片段(NDSK),并部分溶解了电泳条带,主要位于纤维蛋白原和ND纤维蛋白的NDSK之间,证明了它们的存在。最近开发出一种鉴定仅缺乏一种FPA分子的方法(GPRphoresis),从而为确认和更好地量化异二聚体提供了机会,该方法在这里用于研究新出现的Aalpha16R-> H纤维蛋白原性血病的案例,“纤维蛋白原”阿马里洛。” GPRphoresis使用电泳位移,与GPRP-NH(2)结合,将缺乏两种FPA的自聚集纤维蛋白单体与缺乏一种FPA的弱聚集“ semifibrin”分子分开。使用抗纤维蛋白alpha17-23抗体来测量和区分半纤维蛋白与纤维蛋白原FPA完好无损。将GPRphoresis应用于纤维蛋白原Amarillo的腐殖质消化物中,可以清楚地证明RFPARFPA,RFPAHFPA和HFPAHFPA分子的比例几乎达到了孟德尔理想的1:2:1比例。反过来,在末端Atroxin消化物中高水平的半纤维蛋白提供了支持GPRphoresis方法保真度的遗传表型证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号